Trial Profile
Additional analysis of Phase II safety and efficacy study of alectinib in poor performance status patients with ALK positive, advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2018
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LOGiK1401-A
- 06 Jun 2018 Status changed from active, no longer recruiting to completed.
- 08 Jun 2015 New trial record